'Intelligent Monitoring' Gains Momentum as Pharma Industry Seeks to Realize Risk-Based Monitoring Benefits
─ BioClinica Technology Reduces Risk, Raises Quality in Clinical Trials ─
NEWTOWN, Pennsylvania, Nov. 20, 2014 /PRNewswire/ -- BioClinica®, Inc., a leading provider of outsourced clinical trial services and eClinical technologies, reports growing demand for its 'Intelligent Monitoring' approach to risk-based monitoring in clinical trials. Intelligent monitoring extends the concept of Risk-Based Monitoring beyond merely reducing site monitoring visits or changing monitoring methods. It is an approach aimed at reducing risks and increasing overall quality in clinical trials.
Logo - http://photos.prnewswire.com/prnh/20130403/PH87647LOGO
"As clinical trial professionals better understand the original intent of risk-based monitoring, which at its core is to reduce and mitigate risks in a clinical trial, they are increasingly turning to Compass technology to help them do that," said BioClinica Vice President of Innovation, Courtney McBean. "Our unique approach brings together the right people, process, and technology, giving study teams actionable analytics to make better decisions about how their trials are run."
McBean explained the benefits of intelligent monitoring in a recent webinar: "An Intelligent Approach to Risk-Based Monitoring." In her presentation she outlined eight key steps for a risk-based monitoring implementation and explained how intelligent monitoring accounts for the factors critical to successful risk-based monitoring. Over 400 registrants from 245 companies and 25 countries signed up for the webinar, which was followed by a lively question and answer session focused on this topic and innovative approaches. A recording of the webinar is available on demand at www.BioClinica.com.
BioClinica will present more about Intelligent Monitoring at the Scope Summit for Clinical Operations Executives in Orlando, Florida on February 25, 2015 and at the company's European 'Trial Blazers' User Conference in Barcelona, February 24rd – 25th, where Mireille Zerola, Project Team Leader for the implementation of Risk-Based Monitoring (RBM) at Boehringer Ingelheim and member of TransCelerate Biopharma's RBM work stream, will present on "Putting Risk-Based Monitoring into Practice."
The flood of interest in our intelligent monitoring approach has been tremendous," said Steve Boccardo, Senior Vice President of Business Development. "Whether in Barcelona at the recent Partnerships in Clinical Trials, SCDM, or another industry events, sponsors and CROs can't hear enough about making risk-based monitoring a reality. The interest in Compass is truly remarkable."
To request a meeting with BioClinica call our hotline at 1-888-392-7456, email sales@bioclinica.com or complete the online Contact Us form. Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading medical imaging services, cardiac safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies – including all the top 20 – through a network of offices in the U.S., Europe, and Asia. For more information, please visit www.bioclinica.com.
Share this article